Previous 10 | Next 10 |
New In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at RHO p.P23H Mutation and up to 65% at RHO p.V345L and p.P347L, Well Above Threshold Requir...
CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Company will showcase advances in preclinical data across the Prime ...
2023-10-04 17:50:03 ET Gainers: Prime Medicine ( NASDAQ: PRME ) +5% . uniQure ( QURE ) +5% . Aclaris Therapeutics ( ACRS ) +4% . ALX Oncology Holdings ( ALXO ) +3% . Aurora Innovation ( AUR ) +3% . Losers: MaxCy...
2023-09-27 08:49:39 ET Summary Prime Medicine is developing prime editing, a highly precise gene editing technology that offers advantages over traditional CRISPR-Cas9 gene editing. Prime editing has shown promising results in human cell lines, including correcting genetic causes ...
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime...
2023-08-07 17:36:27 ET Prime Medicine press release ( NASDAQ: PRME ): Q2 GAAP EPS of -$0.47 misses by $0.04 . As of June 30, 2023, cash, cash equivalents, investments and restricted cash were $221.1 million, as compared to $263.0 million as of March 31, 2023. For...
-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multip...
2023-07-25 07:45:00 ET Cathie Wood is a big believer in the genomics revolution. Thanks to the advent of next-generation sequencing, researchers now have access to not only entire genomes in a cost and time-effective manner, but they also have the option of exploring how the expression of t...
2023-07-13 03:27:21 ET Summary Prime Medicine pioneers Prime Editors, a revolutionary gene therapy with broad editing potential, offering high therapeutic impact on diseases by correcting diverse mutations at the genomic level. Prime's Q1 2023 financial report shows increased expe...
-- Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimens and introduce new therapeutic options that can expand the...
News, Short Squeeze, Breakout and More Instantly...
First Trust Heitman Global Prime Real Estate ETF Company Name:
PRME Stock Symbol:
NYSE Market:
First Trust Heitman Global Prime Real Estate ETF Website:
2024-07-17 00:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 05:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 12:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...